48P Phase II trial on vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma (COMBI-GVAX): Clinical results of the first step
Immuno-Oncology and Technology(2022)
摘要
Glioblastoma (GBM) is a poor prognosis malignant grade IV glioma. After surgical resection, standard therapy consists of concomitant radiotherapy (RT) and temozolomide (TMZ) followed by TMZ alone. Multiple phase I/II trials and at least 3 meta-analysis showed improved survival (OS) and progression free survival (PFS) with dendritic cell (DC) vaccination in high-grade gliomas (HGGs) patients (pts). In those developing antitumor immunity, DC vaccine increases the amount of intratumoral activated cytotoxic T lymphocytes and decreases the number of FoxP3 positive regulatory T cells.
更多查看译文
关键词
autologous dendritic cells,glioblastoma,vaccination,autologous tumour homogenate,combi-gvax
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要